Insider Buying: biote Corp. (NASDAQ:BTMD) Major Shareholder Buys 8,801 Shares of Stock

biote Corp. (NASDAQ:BTMD) major shareholder Guines Llc bought 8,801 shares of biote stock in a transaction dated Monday, April 21st. The stock was purchased at an average cost of $3.27 per share, for a total transaction of $28,779.27. Following the purchase, the insider now owns 4,173,101 shares of the company’s stock, valued at approximately $13,646,040.27. This trade represents a 0.21 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Guines Llc also recently made the following trade(s):

• On Thursday, April 17th, Guines Llc acquired 6,874 shares of biote stock. The stock was purchased at an average cost of $3.29 per share, for a total transaction of $22,615.46.
• On Wednesday, April 9th, Guines Llc bought 13,532 shares of biote stock. The shares were acquired at an average price of $3.21 per share, with a total value of $43,437.72.
• On Monday, April 7th, Guines Llc purchased 43,378 shares of biote stock. The stock was acquired at an average price of $3.15 per share, for a total transaction of $136,640.70.
• On Thursday, April 3rd, Guines Llc acquired 7,321 shares of biote stock. The shares were acquired at an average price of $3.24 per share, with a total value of $23,720.04.
• On Monday, March 31st, Guines Llc bought 106,000 shares of biote stock. The stock was acquired at an average price of $3.32 per share, for a total transaction of $351,920.00.
• On Monday, March 17th, Guines Llc bought 100 shares of biote stock. The shares were bought at an average cost of $3.74 per share, with a total value of $374.00.
• On Thursday, March 13th, Guines Llc purchased 750,000 shares of biote stock. The stock was bought at an average cost of $3.22 per share, for a total transaction of $2,415,000.00.

biote Stock Down 0.6 %

Shares of NASDAQ:BTMD opened at $3.43 on Friday. The business’s 50 day moving average is $3.80 and its 200 day moving average is $5.06. The stock has a market cap of $187.66 million, a P/E ratio of 13.19 and a beta of 1.17. biote Corp. has a 52-week low of $3.04 and a 52-week high of $8.44.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum dropped their target price on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th.

Hedge Funds Weigh In On biote

A number of hedge funds and other institutional investors have recently made changes to their positions in BTMD. Kanen Wealth Management LLC purchased a new stake in biote in the fourth quarter worth about $1,791,000. Hillsdale Investment Management Inc. bought a new stake in shares of biote in the 4th quarter valued at about $1,561,000. Marshall Wace LLP bought a new stake in shares of biote in the 4th quarter valued at about $543,000. Trexquant Investment LP lifted its position in shares of biote by 423.1% in the 4th quarter. Trexquant Investment LP now owns 101,757 shares of the company’s stock worth $629,000 after purchasing an additional 82,303 shares during the period. Finally, Walleye Capital LLC bought a new position in shares of biote during the fourth quarter valued at approximately $445,000. Institutional investors own 21.68% of the company’s stock.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.